Phase 3 Recruiting Industry
This is a Phase III, randomised, open-label, sponsor-blinded, 3-arm, multicentre, global study assessing the efficacy and safety of rilvegostomig in combination with bevacizumab with or without tremelimumab compared to atezolizumab in comb…
Sponsor: AstraZeneca
NCT ID: NCT06921785
Sites in Washington: - Research Site — Seattle, Washington
Phase 2 Recruiting Industry
The purpose of this study is to assess the safety of atezolizumab and bevacizumab, or atezolizumab alone, as first-line treatment in participants with unresectable, locally advanced or metastatic hepatocellular carcinoma (HCC) with Child-p…
Sponsor: Genentech, Inc.
NCT ID: NCT06096779
Sites in Washington: - Virginia Mason Medical Center — Seattle, Washington
Phase 1, Phase 2 Recruiting Industry
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1303/BNT323 in subjects with advanced solid tumors that express HER2.
Sponsor: DualityBio Inc.
NCT ID: NCT05150691
Sites in Washington: - Swedish Cancer Institute — Seattle, Washington
Phase 1, Phase 2 Recruiting Industry
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1311/BNT324 in subjects with advanced solid tumors.
Sponsor: DualityBio Inc.
NCT ID: NCT05914116
Sites in Washington: - Research Site 105 — Spokane, Washington
Phase 1, Phase 2 Recruiting Network
This phase I/II trial evaluates the highest safe dose, side effects, and possible benefits of tegavivint in treating patients with solid tumors that has come back (recurrent) or does not respond to treatment (refractory). Tegavivint interf…
Sponsor: Children's Oncology Group
NCT ID: NCT04851119
Sites in Washington: - Seattle Children's Hospital — Seattle, Washington
Phase 1, Phase 2 Recruiting Industry
The primary objectives of Cohort A Phase 1b and exploratory expansion are to evaluate the safety and tolerability of TTI-101 orally administered as a single agent to participants with locally advanced or metastatic, and unresectable Hepato…
Sponsor: Tvardi Therapeutics, Incorporated
NCT ID: NCT05440708
Sites in Washington: - Virginia Mason Medical Center — Seattle, Washington
- Summit Cancer Centers - North Spokane — Spokane, Washington
Phase 1, Phase 2 Recruiting Network
This phase I/II trial tests the safety, side effects and best dose of DT2216 in combination with irinotecan and how well it works in treating children, adolescents and young adults with solid tumors and fibrolamellar cancer that has come b…
Sponsor: Children's Oncology Group
NCT ID: NCT06620302
Sites in Washington: - Seattle Children's Hospital — Seattle, Washington
Phase 2 Recruiting Industry
This study is designed to assess the efficacy and safety of ifinatamab deruxtecan (I-DXD) in the following tumor types: endometrial cancer (EC); head and neck squamous cell carcinoma (HNSCC); pancreatic ductal adenocarcinoma (PDAC); colore…
Sponsor: Daiichi Sankyo
NCT ID: NCT06330064
Sites in Washington: - Wenatchee Hospitals and Clinics — Wenatchee, Washington
Phase 2 Recruiting Industry
A Phase II, Multicenter, Open-Label Trial of DB-1311 in combination with BNT327 or DB-1305 in Participants with Advanced/Metastatic Solid Tumors
Sponsor: DualityBio Inc.
NCT ID: NCT06953089
Sites in Washington: - USA09-0 — Puyallup, Washington
- USA07-0 — Spokane, Washington
Phase 1, Phase 2 Recruiting Industry
Phase 1/2 randomized, controlled, open-label trial of theranostic pair RYZ811 (diagnostic) and RYZ801 (therapeutic) to identify and treat subjects with GPC3+ unresectable hepatocellular carcinoma (HCC)
Sponsor: RayzeBio, Inc.
NCT ID: NCT06726161
Sites in Washington: - Research Facility — Seattle, Washington
Phase 1, Phase 2 Recruiting Industry
The purpose of this study is to evaluate the safety and tolerability of Pumitamig alone or in combination with Ipilimumab in participants with first-line advanced or unresectable Hepatocellular Carcinoma (HCC)
Sponsor: Bristol-Myers Squibb
NCT ID: NCT07291076
Sites in Washington: - Local Institution - 0083 — Seattle, Washington
Phase 1, Phase 2 Recruiting Industry
This study will be conducted in 2 parts. The first part is a phase 1 single-agent dose escalation, and dose optimization, study of tegavivint in patients with advanced HCC after failure of at least one line of prior systemic therapy. The s…
Sponsor: Iterion Therapeutics
NCT ID: NCT05797805
Sites in Washington: - Fred Hutchinson Cancer Center — Seattle, Washington
Phase 1, Phase 2 Recruiting Industry
This is an open-label, dose escalation, multi-center, Phase I/II clinical trial aimed at assessing the safety and preliminary efficacy of an investigational ARTEMIS® ECT204 T-cell therapy. The trial is suitable for adult subjects (≥ 18 yea…
Sponsor: Eureka Therapeutics Inc.
NCT ID: NCT04864054
Sites in Washington: - Fred Hutchinson Cancer Center, University of Washington — Seattle, Washington
Phase 1 Recruiting Industry
This is a multicenter, randomized, double-blind, parallel-controlled, phase I clinical study to evaluate the PK characteristics, safety, efficacy, and immunogenicity of HLX13 and US-sourced YERVOY® in patients with unresectable hepatocellu…
Sponsor: Shanghai Henlius Biotech
NCT ID: NCT07176650
Sites in Washington: - American Oncology Network Vista Oncology Division/Physician Partner Associate — Olympia, Washington
- Northwest Medical Specialties PLLC (NWMS) — Tacoma, Washington
Phase 1 Recruiting Academic/Other
This Phase 1, open-label, non-randomized study will enroll pediatric and young adult subjects with relapsed or refractory non-central nervous system (CNS) malignant solid tumors expressing glypican-3 (GPC3) to examine the safety, feasibili…
Sponsor: Seattle Children's Hospital
NCT ID: NCT07148050
Sites in Washington: - Seattle Children's Hospital — Seattle, Washington
Recruiting Industry
International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and its clinic…
Sponsor: Massive Bio, Inc.
NCT ID: NCT03452774
Sites in Washington: - Massive Bio SYNERGY-AI site — Seattle, Washington
Recruiting Industry
The goal of this observational study is to collect information on the use of the HistoSonics Edison System for the treatment of liver tumors. The main aim is to understand how different patient characteristics and procedural characteristic…
Sponsor: HistoSonics, Inc.
NCT ID: NCT06486454
Sites in Washington: - Swedish Medical Center — Seattle, Washington
Recruiting Industry
Given the number of anticipated durvalumab-based treatment launches in the hepatobiliary cancer space over the next 3 years, there is a need to capture contemporary real-world data across these indications. LIVER-R is a multicountry, multi…
Sponsor: AstraZeneca
NCT ID: NCT06252753
Sites in Washington: - Research Site — Spokane, Washington
NA Recruiting Federal
The study is a randomized trial of two different screening methods for early detection of liver cancer in patients with cirrhosis of the liver. The goal of PREMIUM is to compare an abbreviated version of the diagnostic gold standard for HC…
Sponsor: VA Office of Research and Development
NCT ID: NCT05486572
Sites in Washington: - VA Puget Sound Health Care System Seattle Division, Seattle, WA — Seattle, Washington